Synonym
Toludesvenlafaxine hydrochloride; Toludesvenlafaxine HCl; LPM 570065; LPM-570065; LPM570065; LY03005 hydrochloride dihydrate; LY 03005 hydrochloride dihydrate; LY-03005 hydrochloride dihydrate
IUPAC/Chemical Name
Benzoic acid, 4-methyl-, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenyl ester, hydrochloride, hydrate (1:1:2)
InChi Key
KNUFVVBEPJZGLI-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H31NO3.ClH.2H2O/c1-18-7-9-20(10-8-18)23(26)28-21-13-11-19(12-14-21)22(17-25(2)3)24(27)15-5-4-6-16-24;;;/h7-14,22,27H,4-6,15-17H2,1-3H3;1H;2*1H2
SMILES Code
O=C(OC1=CC=C(C(C2(O)CCCCC2)CN(C)C)C=C1)C3=CC=C(C)C=C3.[H]Cl.[H]O[H].[H]O[H]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
454.00
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Guo W, Gao Y, Jiang W, Li C, Lin F, Zhu H, Wang H, Ye L, Qi JG, Cen X, Tian J. Toxicity effects of a novel potent triple reuptake inhibitor, LPM570065, on the fertility and early embryonic development in Sprague-Dawley rats. Regul Toxicol Pharmacol. 2018 Dec;100:45-51. doi: 10.1016/j.yrtph.2018.10.008. Epub 2018 Oct 23. PubMed PMID: 30359699.
2: Li C, Jiang W, Gao Y, Lin F, Zhu H, Wang H, Ye L, Qi JG, Tian J. Acute, subchronic oral toxicity, and genotoxicity evaluations of LPM570065, a new potent triple reuptake inhibitor. Regul Toxicol Pharmacol. 2018 Oct;98:129-139. doi: 10.1016/j.yrtph.2018.07.011. Epub 2018 Jul 17. PubMed PMID: 30030102.
3: Zhang R, Li X, Shi Y, Shao Y, Sun K, Wang A, Sun F, Liu W, Wang D, Jin J, Li Y. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats. PLoS One. 2014 Mar 10;9(3):e91775. doi: 10.1371/journal.pone.0091775. eCollection 2014. PubMed PMID: 24614602; PubMed Central PMCID: PMC3948889.
4: Fasipe OJ. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep. 2019 Jan 9;6:95-110. doi: 10.1016/j.ibror.2019.01.001. eCollection 2019 Jun. Review. PubMed PMID: 31211282; PubMed Central PMCID: PMC6562183.
